Biggest News Aggregation in the World
๐Ÿ“ฐ First In Human Study News

First In Human Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from First In Human Study. Real-time updates on events, politics, business and more.

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of HopeSAN MATEO, Calif., and...
United Kingdom United States Sarah Connors Kronos Bio Miguel Villalona Calero Corporate Communications

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023 - Arrowhead Pharma (NASDAQ:ARWR)

- Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung - Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma Demonstrate Deep and Durable Gene Silencing - Promising Preclinical
International Congress Arrowhead Pharmaceuticals Subcutaneous Administration Mediates Pulmonary European Respiratory Society Arrowhead Pharmaceuticals Inc European Respiratory Society International Congress

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: Citiโ€™s 18th Annual BioPharma Conference โ€“ September 6, 2023 Type: 1-on-1...
Arrowhead Pharmaceuticals Subcutaneous Administration Mediates Pulmonary Exchange Commission Arrowhead Pharmaceuticals Inc Morgan Stanley European Respiratory Society

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its...
District Of Columbia United States South Korea United Kingdom New Zealand University College

NexImmune : Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 - Form 8-K

- Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 ... | June 5, 2023
United States Ohio State University Emily Lu Sumithira Vasu Suzanne Afonso Smith Juanc Varela

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science